Get the Stockscreener App
1.10
8.33%
-0.10
After Hours:
1.16
0.06
+5.45%
Pds Biotechnology Corp stock is traded at $1.10, with a volume of 985.11K.
It is down -8.33% in the last 24 hours and up +22.15% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
See More
Previous Close:
$1.20
Open:
$1.21
24h Volume:
985.11K
Relative Volume:
1.18
Market Cap:
$61.40M
Revenue:
-
Net Income/Loss:
$-33.36M
P/E Ratio:
-1.6403
EPS:
-0.6706
Net Cash Flow:
$-23.09M
1W Performance:
+10.00%
1M Performance:
+22.15%
6M Performance:
+35.25%
1Y Performance:
-30.38%
1-Day Range:
$1.08
$1.22
1-Week Range:
$1.01
$1.28
52-Week Range:
$0.5068
$1.915
Pds Biotechnology Corp Stock (PDSB) Company Profile
Name
Pds Biotechnology Corp
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corp
|
1.10 | 66.98M | 0 | -33.36M | -23.09M | -0.6706 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pds Biotechnology Corp Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corp Stock (PDSB) Latest News
PDS Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 3.45%Earnings Growth Forecast - Newser
PDS Biotechnology Q1 2026 Earnings: EPS Beat Highlights Progress Despite Pre-Revenue StatusSpecial Dividend Alert - Newser
ETFs Investing in PDS Biotechnology Corp. Stocks - TradingView
PDS Biotechnology Q1 2026 earnings preview - MSN
Number of shareholders of PDS Biotechnology Corp. – SWB:EU6 - TradingView
PDS Biotechnology: Juni-Test für Wandelanleihe - kapitalmarktexperten.de
PDSB Stock Price, Quote & Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corp reports results for the quarter ended March 31Earnings Summary - TradingView
PDS Biotechnology (PDSB) posts Q1 2026 loss and plans costly debt redemption - Stock Titan
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript - Sahm
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients - MSN
PDSB Q1 2026 Earnings Transcript - AOL.com
PDS Biotechnology Q1 Earnings Call Highlights - MarketBeat
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
PDS Biotech Reports Q1 2026 Financial Results, Highlights Clinical Progress in Cancer Immunotherapy Trials - Minichart
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations By Investing.com - Investing.com South Africa
PDSB: Protocol changes accelerate clinical timelines and reduce costs, with improved financials - TradingView
Earnings call transcript: PDS Biotechnology beats Q1 2026 EPS expectations - Investing.com
PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5% - ChartMill
PDS Biotechnology posts quarterly financial results and updates clinical programs - Traders Union
PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings - Quiver Quantitative
PDS Biotechnology reports Q1 2026 net loss $7.3M, cash $21.7M; clinical updates on PDS0101 and PDS01ADC - TradingView
PDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical Update - Quiver Quantitative
PDS Biotechnology: Q1 Earnings Snapshot - marketscreener.com
PDSB: Q1 2026 featured clinical milestones, reduced net loss, and extended patent protection - TradingView
PDS Biotech (Nasdaq: PDSB) trims Q1 loss as R&D spending falls - Stock Titan
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - marketscreener.com
PDS Biotech trial reports 77.8% response in colorectal cancer - Stock Titan
PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
TradingKey - TradingKey
PDS Biotechnology Pushes Toward Pivotal Cancer Trial Results With Cash in Focus - AD HOC NEWS
PDS Biotechnology Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
PDS Biotechnology to provide quarterly results and clinical program progress - Traders Union
PDS Biotech to Discuss First Quarter 2026 Financial Results on May 6th - geneonline.com
PDS Biotech to give Q1 results and clinical update May 13 - Stock Titan
- SEC.gov
PDS Biotechnology Refinances Debt with New Note, Warrant - The Globe and Mail
PDS Biotechnology Secures $6 Million Note and New ATM; To Redeem 2025 Debentures - TradingView
PDS Biotech (PDSB) adds $6M note, warrants and new ATM while redeeming debentures - Stock Titan
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April - MarketBeat
PDSB Stock Chart | PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) - ChartMill
PDS Biotechnology Corporation announced that it expects to receive $5.76 million in funding - marketscreener.com
[EFFECT] PDS Biotechnology Corp SEC Filing - Stock Titan
PDS Biotech 2025 Executive Compensation, Leadership Structure, and Equity Ownership Overview - Minichart
[10-K/A] PDS Biotechnology Corp Amends Annual Report - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) registers $200M shelf, removes $20M ATM - Stock Titan
PDS Biotechnology: FDA-Alignment für VERSATILE-003 - Börse Global
PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment - MSN
PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts - TradingView
PDS Biotech (NASDAQ: PDSB) spotlights PDS0101 Phase 3 and IL-12 ADC - Stock Titan
Pds Biotechnology Corp Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):